BioGaia AB Interim Management Statement – January – June 2022
SECOND QUARTER 2022 · Net sales amounted to SEK 288.1 million (203.1), an increase of SEK 85.0 million,...
Read moreSECOND QUARTER 2022 · Net sales amounted to SEK 288.1 million (203.1), an increase of SEK 85.0 million,...
Read moreThe US is the first market to launch BioGaia Pharax, which aims to strengthen the immune system and support children’...
Read moreBioGaia has extended its collaboration with Grace International, giving the company exclusive rights to market and sell its probiotic drops...
Read moreThe number of shares and votes in BioGaia has increased during May due to the share split resolved by BioGaia’...
Read moreStarting in 2023, BioGaia will be selling probiotics under its own management in Canada. Following the acquisition of Nutraceutics in...
Read moreWe are proud to announce that our probiotic for bone health, Osfortis, is the winner of the 2022 NutraIngredients Awards...
Read moreAt BioGaia’s Annual General Meeting held earlier today, on 6 May 2022, it was resolved on a share split...
Read moreThe Annual General Meeting of BioGaia AB (publ) on 6 May 2022 voted, among other things, to approve the following...
Read more